Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 17

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 17
---
 and the Compensation Committee recognize the potential benefits of having less frequent advisory votes to approve executive compensation (including allowing the Company additional time to effectively evaluate the relationship between the executive compensation and long-term Company performance and stockholder return), we recognize that the widely adopted standard is to hold Say-on-Pay votes annually. The Board and Compensation Committee also acknowledge current stockholder expectations regarding having the opportunity to express their views on the Company’s executive compensation on an annual basis. In light of investor expectations and prevailing market practice, our Board and the Compensation Committee recommend that the advisory vote to approve executive compensation occur every year. Vote Required; Recommendation of the Board Proposal Three must be approved by the Required Vote, assuming a quorum is present. For this purpose, abstentions will be counted as a vote against the proposal, while broker non-votes will have no effect on the outcome of the vote. Because Proposal Three has three possible substantive responses (every one, two or three years), if none of the frequency alternatives receives the Required Vote, then we will consider stockholders to have approved the frequency that receives the greatest number of the votes cast.

| THE BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS SELECT“1 YEAR”ON THE PROPOSAL CONCERNING THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION |

| 21 |

2025 PROXY STATEMENT Executive Compensation COMPENSATION DISCUSSION AND ANALYSIS

The following compensation discussion and analysis contains statements regarding future individual and Company performance targets and goals. These targets and goals are disclosed in the limited context of Arrowhead’s executive compensation program and should not be understood to be statements of management’s expectations or guidance. Arrowhead cautions investors not to apply these statements to other contexts. Fiscal years are denoted as fiscal years, all other year references refer to calendar years. This Compensation Discussion and Analysis describes the compensation program for our NEOs. During fiscal 2024, these individuals were: • Christopher Anzalone, our President and Chief Executive Officer (our “ CEO ”); • James Hamilton, our Chief of Discovery and Translational Medicine (our “ CDTM ”); • Kenneth Myszkowski, our Chief Financial Officer (our “ CFO ”); • Patrick O’Brien, our Chief Operating Officer and General Counsel (our “ COO ” and “ GC ”); • Tracie Oliver, our former Chief Commercial Officer (our " CCO "); and • Javier San Martin, our former Chief Medical Officer (